About PreciseDx
PreciseDx is a company based in New York (United States) founded in 2019 by Michael Donovan, Jack Zeineh, Gerardo Fernandez, and Carlos Cordon-Cardo. PreciseDx has raised $31.95 million across 2 funding rounds from investors including Philips, LabCorp and Quest Diagnostics. PreciseDx offers products and services including PreciseBreast and OncoIntelligence. PreciseDx operates in a competitive market with competitors including PathAI, PAIGE, EnSpectra Health, Proscia and Qritive, among others.
- Headquarter New York, United States
- Founders Michael Donovan, Jack Zeineh, Gerardo Fernandez, Carlos Cordon-Cardo
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Precisedx, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$31.95 M (USD)
in 2 rounds
-
Latest Funding Round
$11.23 M (USD), Series B
May 28, 2025
-
Investors
Philips
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PreciseDx
PreciseDx offers a comprehensive portfolio of products and services, including PreciseBreast and OncoIntelligence.
AI tool for breast cancer risk classification from slides
System for predicting tumor recurrence in breast cancer
People of PreciseDx
Unlock access to complete
Unlock access to complete
Funding Insights of PreciseDx
PreciseDx has successfully raised a total of $31.95M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $11.23 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PreciseDx
PreciseDx has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Philips, LabCorp and Quest Diagnostics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Eventide is engaged in values-based investment management services.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for PreciseDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PreciseDx
Investment portfolio details for PreciseDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PreciseDx
Detailed financials for PreciseDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Precisedx Comparisons
Peer comparison for PreciseDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PreciseDx
PreciseDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PathAI, PAIGE, EnSpectra Health, Proscia and Qritive, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of AI-based solutions for clinical diagnosis of cancer and other diseases
|
|
| Locked | Locked | Locked |
AI-enabled tools for computational pathology and cancer diagnostics are provided.
|
|
| Locked | Locked | Locked |
Developer of medical devices for tissue imagining and cancer detection
|
|
| Locked | Locked | Locked |
Provider of an AI and cloud-based digital pathology solution for cancer diagnosis
|
|
| Locked | Locked | Locked |
AI-based oncology diagnostic solution based on microscopic images & patient data
|
Detailed competitors of PreciseDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Precisedx
Complete news archive for PreciseDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PreciseDx
PreciseDx was founded in 2019 and raised its 1st funding round 5 years after it was founded.
PreciseDx is headquartered in New York, United States. It is registered at New York, New York, United States.
Eric T. Converse is the current CEO of PreciseDx.
PreciseDx is a funded company, having raised a total of $31.95M across 2 funding rounds to date.
PreciseDx was founded in 2019 in New York, United States, within the healthcare technology sector. An AI-based software platform is developed for analyzing medical images, particularly pathological samples. Diseases are predicted through AI-driven examination of patient images. Image enhancement features are incorporated, alongside workflow management tools. Diagnosis and treatment planning for healthcare professionals are supported across operations in the United States.
PreciseDx offers PreciseBreast and OncoIntelligence.
PreciseDx has 6 investors. Key investors include Philips, LabCorp, Quest Diagnostics, Eventide, and GenHenn Capital.